1046817-01-9 Usage
General Description
1-(5-ethylpyrimidin-2-yl)piperidin-4-yl methanesulfonate is a chemical compound with a molecular formula C15H25N3O3S. It is commonly used as a pharmaceutical intermediate in the synthesis of various drugs, including antihistamines and antiarrhythmics. 1-(5-ethylpyrimidin-2-yl)piperidin-4-yl methanesulfonate is a derivative of piperidine, a heterocyclic organic compound with a six-membered ring structure containing nitrogen atoms. The addition of the ethylpyrimidin-2-yl group to the piperidin-4-yl moiety enhances its pharmacological properties, making it a valuable building block for drug development. Additionally, the methanesulfonate group contributes to the compound's stability and solubility, making it suitable for pharmaceutical applications. Overall, 1-(5-ethylpyrimidin-2-yl)piperidin-4-yl methanesulfonate plays a crucial role in the synthesis of various medications with therapeutic benefits.
Check Digit Verification of cas no
The CAS Registry Mumber 1046817-01-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,6,8,1 and 7 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1046817-01:
(9*1)+(8*0)+(7*4)+(6*6)+(5*8)+(4*1)+(3*7)+(2*0)+(1*1)=139
139 % 10 = 9
So 1046817-01-9 is a valid CAS Registry Number.
1046817-01-9Relevant articles and documents
BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS
-
Page/Page column 30, (2012/08/27)
The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula (I), pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metabolic disorders and complications thereof, as well as methods for the treatment of the metabolic disorders and complications thereof.
N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS
-
Page/Page column 78, (2009/03/07)
Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.